Preferred Label : Vibostolimab;
NCIt synonyms : TIGIT Inhibitor MK-7684; T-cell Immunoglobulin and Immunoreceptor Tyrosine-based Inhibitory Motif Inhibitor
MK-7684; TIGIT-targeting Agent MK-7684;
NCIt definition : An antagonistic agent targeting the co-inhibitory molecule and immune checkpoint inhibitor
T-cell immunoglobulin (Ig) and immunoreceptor tyrosine-based inhibitory motif (ITIM)
domains (TIGIT; T-cell immunoreceptor with Ig and ITIM domains; T-cell immunoglobulin
and ITIM domain), with potential immune checkpoint inhibitory and antineoplastic activities.
Upon administration, vibostolimab targets and binds to TIGIT expressed on various
immune cells, particularly on tumor-infiltrating T-lymphocytes (TILs) and natural
killer (NK) cells, thereby preventing the interaction of TIGIT with its ligands CD112
(nectin-2; poliovirus receptor related-2; PVRL2) and CD155 (poliovirus receptor; PVR;
nectin-like protein 5; NECL-5), which are expressed on T-cells, NK cells and certain
cancer cells. This enhances the interaction of CD112 and CD155 with the costimulatory
receptor CD226 (DNAX Accessory molecule-1; DNAM-1), which is expressed on immune cells,
such as NK cells and CD8 T-cells, and activates CD226-mediated signaling. This activates
the immune system to exert a T-cell-mediated immune response against cancer cells.
TIGIT, a member of the Ig super family and an immune inhibitory receptor, is overexpressed
on tumor antigen-specific CD8 T-cells and CD8 TILs and plays a key role in the suppression
of T-cell proliferation and activation; it is involved in tumor cell immune evasion,
and the inhibition of antiviral immune responses.;
UNII : 5XO3JF0FEK;
CAS number : 2231305-30-7;
Molecule name : MK-7684; MK 7684;
NCI Metathesaurus CUI : CL538225;
Origin ID : C140041;
UMLS CUI : C5432276;
Semantic type(s)
- chemical_or_drug_has_mechanism_of_action
- concept_is_in_subset
- has_target
